- Fair Weather on Mayweather
- The Literature
- Give It to Me Straight, Doc
- Before initiating therapy, identify if the etiology is infectious or noninfectious.
- What is the Current Role of Laser Therapy in the Management of DME?
- Why Are There Not More Pharmacotherapies for Glaucoma?
- Dropless Cataract Surgery Offers Benefits for Patients, Providers
- Why I Use Intracameral Antibiotics
- Bacterial Resistance Develops Through Multiple Mechanisms
- Sidebar: Besifloxacin for the Treatment of Bacterial Keratitis
- Are Generic Medications Contributing to the Rise of Superbugs?
- Sidebar: From TRUST to ARMOR: Where We Stand
- Cash-Strapped Millennials Make Do with Contact Lenses in Lieu of LASIK
- Best Practices for Integrated Care With Optometrists
- The Optometrist’s Role in Collaborative Care for Refractive Surgery
- Attracting Millennials to Your Refractive Surgery Center
- High-definition Wavefront Aberrometry Provides Encouraging Early Results
- High-tech In Low Vision
- Outreach Efforts Have Changed Many Lives
GLAUCOMA AND ASSOCIATED VISUAL ACUITY AND FIELD LOSS SIGNIFICANTLY AFFECT GLAUCOMA-SPECIFIC PSYCHOSOCIAL FUNCTIONING
Chan EW, Chiang PPC, Liao J, et al1
Chan et al reported a cross-sectional study comparing psychosocial functioning (PF) between 192 patients who had bilateral glaucoma with visual acuity (VA) or visual field (VF) losses and 40 controls. Four psychosocial outcomes of the Glaucoma Quality-of-Life 36-item questionnaire were psychometrically evaluated in order to assess the impact of glaucoma, VA, and VFs on PF. The main outcome measures included anxiety, self-image, psychosocial well-being, and confidence in health care—the only domains from this questionnaire pertaining to PF.
The participants’ mean age was 66.2 ±11 years, and 63% were male. The VA in the better-seeing eye and mean deviation were Snellen 20/25 and -8.89 ±6.52 dB, respectively. In multivariate models, glaucoma patients had 63% greater anxiety (P < .001), a 71% lower self-image (P < .001), 38.3% less psychological well-being (P < .001), and 32.4% reduced confidence in health care (P < .001) compared to controls. The worst VA and VF categories had the most reduced PF (range, 26%-81.5%; P < .001 for all associations). Worsening VA was associated with a linear increase in anxiety (P = .003) and decrease in self-image (P = .005). Worsening VFs from 0 to -12.1 dB (P = .003) was associated with increased anxiety before eventually plateauing. Self-image and confidence in health care also decreased when VFs worsened from 0 to -10 dB (P < .001) and from 0 to -9.3 dB (P = .008), respectively, but actually improved at greater levels of VF loss beyond these thresholds.
How does PF differ from vision-specific functioning?
Psychosocial functioning refers to the psychological and social effects of a disease on a patient, and it represents a key aspect of the World Health Organization’s conception of health-related quality of life, which in ophthalmology has focused on vision-specific activities, including mobility, reading, and driving. These tasks are distinctly different from the psychological, social, and emotional aspects of a disease, and reduced PF is an increasingly recognized clinical consequence of chronic diseases that adversely affects an individual’s overall physical and mental health.2-4 PF and vision-specific functioning are interdependent. Daily functioning—including the use of topical medications, mobility, and driving cessation—are strongly affected by glaucoma,5 and understanding the extent to which PF is linked to activity limitation may be important for developing targeted strategies by which to help glaucoma patients improve their PF.
How is PF affected in early versus late stages of glaucoma?
In this study, glaucoma patients scored lower on all four outcome measures, even after adjusting for sociodemographic and health factors compared with controls. The results indicate that, in the early stages of glaucoma, when VF loss is mild, anxiety increases while self-image and confidence in health care are reduced and VF continues to decline. The authors hypothesize that this may be related to patients’ being more aware of an increase in the number or depth of their scotoma. In early disease, other aspects of visual function such as contrast sensitivity may also become impaired, increasing patients’ concerns regarding intraocular pressure, being treated differently, or the possibility of blindness.
In the late stages of glaucoma, both VFs and eventually VA become affected. The loss of VFs was associated with reduced self-image up to about -10 dB but remained unchanged beyond this level. The authors suggest that patients with advanced glaucoma and tunnel vision may not notice small VF changes. Moreover, those with advanced disease may have increased adaptation to vision loss and may have had more aggressive therapy (eg, glaucoma surgery), thereby instilling in them more confidence in health care. Worsening VA, however, was linearly associated with a lower self-image and greater anxiety, suggesting that, in advanced disease, VA may be a better indicator of PF than VFs. Further research is required to determine the efficacy of different strategies for improving PF in glaucoma patients.
LONGITUDINAL CHANGES IN QUALITY OF LIFE AND RATES OF PROGRESSIVE VISUAL FIELD LOSS IN GLAUCOMA PATIENTS
Medeiros FA, Gracitelli CPB, Boer ER, et al6
Glaucomatous progression can lead to significant visual impairment that results in an increased incidence of falls, a higher risk of motor vehicle collisions, and a reduced ability to perform other activities of daily living.7-11 Medeiros et al performed an observational cohort study that evaluated the association between longitudinal changes in quality of life and rates of progressive VF loss in glaucoma. The study included 322 eyes of 161 patients with glaucomatous VF loss from the Diagnostic Innovations Glaucoma Study. The follow-up period was an average of 3.5 years. All subjects completed the National Eye Institute Visual Function Questionnaire (NEI VFQ)-25 at least twice and had at least five VF examinations during the course of the study. Rates of VF change were determined using the change in mean sensitivity of the integrated binocular VF. To determine the degree of impairment as measured by the NEI VFG-25, a Rasch analysis was performed.
There were three critical findings from this study, which should be highlighted. The authors found a significant correlation between change in the NEI VFQ-25 Rasch scores during follow-up and change in binocular standard automated perimetry (SAP) sensitivity. For every 1-dB change in binocular SAP mean sensitivity per year, there was a change of 2.9 units per year in the Rasch scores. As expected, the amount of baseline VF loss was also important, as subjects with more advanced disease at baseline had more significant changes in NEI VFQ-25 scores. Finally, the rate of change in binocular SAP sensitivity was also found to influence patients’ scores. The authors noted that shorter follow-up times had larger changes in NEI-VFQ-25 scores for patients with the same amount of SAP sensitivity. The findings from this study indicate that clinicians need to assess VF changes carefully over time, as patients’ VF and quality of life are affected by the aforementioned changes in binocular VF.
What is the NEI VFQ-25 Questionnaire?
The National Eye Institute helped create the NEI VFQ-25 with the purpose of developing a survey that would determine the impact of visual impairment/disability on activities related to daily living as well as emotional well-being and social functioning. The survey consists of a base set of 25 vision-targeted questions and an appendix of additional items from the larger 51-item version. The questions represent 11 subscales, which include general vision, near and distance vision activities, ocular pain, vision-related social function, vision-related role function, vision-related mental health, vision-related dependency, driving difficulties, color vision, and peripheral vision. The test takes approximately 10 minutes to administer, but a self-administered version is also available.12,13
What is a Rasch analysis, and how is it helpful?
The Rasch model provides a way to analyze categorical data. An interval scale that determines “item difficulty” and “person measure” is created. Such analysis is especially useful in the case of a questionnaire. Typically, the responses are scored on a Likert scale, and when the scores are added, the relative value of each response category is treated as being the same, and the unit increases from the rating scale are given the same value. When evaluating numerous different aspects pertaining to quality of life, however, it is unlikely that the value of each response category will be the same. When a Rasch model is used, subjects’ responses help dictate item difficulty. The final analysis from the model provides estimates of person measures. These measures can then be used to express where each respondent falls on a linear scale representing the degree of impairment as measured by the questionnaire.14-16 n
1. Chan EW, Chiang PPC, Liao J, et al. Glaucoma and associated visual acuity and field loss significantly affect glaucoma-specific psychosocial functioning. Ophthalmology. 2015;122(3):494-501.
2. Alstrom M, Asplund K, Astrom T. Psychosocial function and life satisfaction after stroke. Stroke. 1992;23:527-31.
3. Carels RA, Mushner-Eizenman D, Cacciapaglia H, et al. Psychosocial functioning and physical symptoms in heart failure patients: a within-individual approach. J Psychosom Res. 2004;56:95-101.
4. Friedman LC, Kalidas M, Elledge R, et al. Optimism, social support, and psychosocial functioning among women with breast cancer. Psychooncology. 2006;15:595-603.
5. West SK, Rubin GS, Broman AT, et al; SEE Project Team. How does visual impairment affect performance on tasks of everyday life? The SEE Project. Arch Opthalmol. 202;120:774-780.
6. Medeiros FA, Gracitelli CPB, Boer ER, et al. Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Am J Ophthalmol. 2015;122(2):293-301.
7. Ramulu P. Glaucoma and disability: which tasks are affected, and at what stage of disease? Curr Opin Ophthalmol. 2009;20:92-98.
8. Haymes SA, LeBlanc RP, Nicolela MT, et al. Glaucoma and on-road driving performance. Invest Ophthalmol Vis Sci. 2008;49:3035-3041.
9. Owsley C, McGwin G. Jr. Vision and driving. Vision Res. 2010;52:2348-2361.
10. Haymes SA, Leblanc RP, Nicolela MT, et al. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci. 2007;48:1149-1155.
11. Goldberg I, Clement CI, Chiang TH, et al. Assessing quality of life in patients with glaucoma using the Glaucoma Quality of Life-15 (GQL-15) questionnaire. J Glaucoma. 2009;18:6-12.
12. Mangione CM, Lee PP, Gutierrez PR, and National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050-1058.
13. Mangione CM, Lee PP, Pitts J, and NEI-VFQ Field Test Investigators. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). Arch Ophthalmol. 1998;116:1496-1504.
14. Boone WJ, Staver JR, Yeale MS. Rasch Analysis in the Human Sciences. Springer, New York; 2014:69-91.
15. Bond TG, Fox CM. Applying the Rasch Model: Fundamental Measurement in the Human Sciences. Taylor & Francis; New York; 2007:29-48.
16. Andrich D. Rating scales and Rasch measurement. Expert Rev Pharmacoecon Outcomes Res. 2011;11:571-585.
Section Editor James C. Tsai, MD, MBA
• President of New York Eye and Ear Infirmary of Mount Sinai and chair of ophthalmology for the Mount Sinai Health System in New York
Helen Kornmann, MD, PhD
• Assistant professor at the Bascom Palmer Eye Institute in Miami, Florida
Joseph F. Panarelli, MD
• Assistant professor of ophthalmology at the New York Eye and Ear Infirmary of Mount Sinai in New York